Human Somatropin biosimilar(Jilin Qijian)

Primary Study Objectives: To investigate the pharmacokinetic characteristics of a single subcutaneous injection of the investigational human growth hormone injection (30 IU/10 mg/3 ml/vial, owned by Jilin Qijian Biotechnology Co., Ltd.) compared to the reference human growth hormone injection (Noze®, 1.5 ml: 5 mg (NordiFlex); manufactured by Novo Nordisk, Denmark) in healthy volunteers, and to evaluate the subcutaneous bioequivalence of the two formulations. Secondary Study Objectives: To investigate the pharmacodynamic characteristics, immunogenicity, and safety of a single subcutaneous injection of the investigational human growth hormone injection (30 IU/10 mg/3 ml/vial) compared to the reference human growth hormone injection (Noze®, 1.5 ml: 5 mg (NordiFlex)) in healthy volunteers.